Hims & Hers Health (NYSE:HIMS) Receives “Neutral” Rating from JPMorgan Chase & Co.

Hims & Hers Health (NYSE:HIMS)‘s stock had its “neutral” rating reissued by JPMorgan Chase & Co. in a note issued to investors on Friday, Benzinga reports. They currently have a $32.00 price target on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 16.27% from the company’s previous close.

Other analysts also recently issued research reports about the stock. Barclays reduced their price objective on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating for the company in a research report on Friday, August 21st. Needham & Company LLC boosted their price target on shares of Hims & Hers Health from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Truist Financial raised their target price on Hims & Hers Health from $27.00 to $32.00 and gave the company a “hold” rating in a research report on Monday, August 24th. Morgan Stanley boosted their target price on shares of Hims & Hers Health from $21.00 to $28.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 11th. Finally, Citigroup decreased their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $32.43.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $27.52 on Friday. The company’s fifty day moving average is $31.05 and its 200 day moving average is $27.16. Hims & Hers Health has a twelve month low of $13.74 and a twelve month high of $65.30. The stock has a market cap of $6.42 billion, a price-to-earnings ratio of -43.69 and a beta of 2.42. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The firm had revenue of $753.21 million for the quarter, compared to the consensus estimate of $698.90 million. During the same quarter in the previous year, the business posted $0.17 EPS. The firm’s revenue for the quarter was up 38.2% compared to the same quarter last year. Sell-side analysts forecast that Hims & Hers Health will post -0.1 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In other news, COO Michael Chi sold 14,027 shares of the business’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total value of $441,850.50. Following the completion of the sale, the chief operating officer owned 432,124 shares of the company’s stock, valued at approximately $13,611,906. The trade was a 3.14% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Deborah M. Autor sold 16,773 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $27.85, for a total transaction of $467,128.05. Following the sale, the insider directly owned 48,961 shares of the company’s stock, valued at $1,363,563.85. The trade was a 25.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 190,227 shares of company stock valued at $6,133,613. 11.76% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Cunning Capital Partners LP acquired a new position in Hims & Hers Health during the fourth quarter worth $1,110,000. Norges Bank purchased a new stake in Hims & Hers Health in the fourth quarter valued at approximately $62,153,000. Virtu Financial LLC purchased a new position in Hims & Hers Health during the 4th quarter valued at about $1,937,000. Louisiana State Employees Retirement System acquired a new position in shares of Hims & Hers Health in the first quarter valued at approximately $1,254,000. Finally, Clear Street Group Inc. grew its stake in shares of Hims & Hers Health by 23.6% in the fourth quarter. Clear Street Group Inc. now owns 1,904,294 shares of the company’s stock worth $61,832,000 after acquiring an additional 363,893 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Neutral Sentiment: Multiple law firms announced or promoted the same federal securities class action against Hims & Hers and certain executives. The proposed class covers investors who purchased HIMS securities from August 4, 2025, through July 29, 2026, with a lead-plaintiff deadline generally listed as November 2, 2026. The repeated announcements increase visibility around the litigation but do not represent separate lawsuits or a finding of wrongdoing. Kaplan Fox class-action announcement
• Negative Sentiment: The core concern is the Federal Trade Commission’s complaint, which reportedly alleges serious business misconduct and deceptive or unlawful privacy practices. The shareholder suit claims Hims & Hers and its executives made materially false or misleading statements or omitted important information, potentially creating legal costs, regulatory risk, reputational damage and uncertainty about future operations. The allegations have not been proven in court. HIMS securities class-action report
• Negative Sentiment: The litigation adds to existing investor concerns following Hims & Hers’ latest earnings report, where revenue exceeded estimates but the company posted a much larger-than-expected loss. A Zacks review said the stock had declined 7.7% since that report, underscoring elevated volatility and sensitivity to execution and regulatory developments. Zacks HIMS earnings-performance review

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings.